Form 4: Pacific Biosciences Executive Receives Stock Options and Restricted Stock Units

James R. Gibson II, a Pacific Biosciences executive, was granted 2,000,000 stock options and 1,000,000 restricted stock units (RSUs) on March 31, 2025.

Summary

• On March 31, 2025, James R. Gibson II, Chief Financial Officer of Pacific Biosciences, received 2,000,000 stock options with an exercise price of $1.18.
• These options vest over four years, starting March 31, 2026, contingent upon continued service.
• Gibson also received 1,000,000 Restricted Stock Units (RSUs) that will vest in equal annual installments on March 31 of each of 2026, 2027, 2028 and 2029, provided that the Reporting Person continues to serve through each vesting date.
• Following these transactions, Gibson directly owns 2,000,000 derivative securities and 1,000,000 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and generally viewed as a positive sign of aligning executive interests with shareholder value. There are no immediate negative implications.

Positives

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Pacific Biosciences' stock price.
• If the executive leaves the company before the vesting dates, they will forfeit the unvested options and RSUs.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options and RSUs suggests an expectation of continued service and performance from the executive.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to attract and retain key executives, aligning their interests with the long-term success of the company. This is especially true for companies like Pacific Biosciences that are focused on innovative technologies and require strong leadership to navigate the competitive landscape.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Illumina and Thermo Fisher Scientific also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs positively, as it aligns executive interests with long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

Pacific Biosciences, PACB, stock options, restricted stock units, RSUs, executive compensation, James R. Gibson II, CFO, Form 4, insider trading